广济药业
(000952)
| 流通市值：22.57亿 | | | 总市值：22.57亿 |
| 流通股本：3.44亿 | | | 总股本：3.44亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 311,953,896.27 | 163,094,175.38 | 623,974,702.31 | 429,263,703.57 |
| 营业总成本 | 378,715,465.03 | 199,970,058.28 | 796,334,880.55 | 552,381,052.88 |
| 其他经营收益 | | | | |
| 营业利润 | -61,269,915.9 | -34,336,783.63 | -443,702,863.04 | -105,012,150.37 |
| 利润总额 | -61,138,794.16 | -34,348,962.15 | -443,104,356.74 | -106,985,800.21 |
| 净利润 | -61,901,634.85 | -33,807,248.66 | -438,947,124.55 | -107,028,427.53 |
| 每股收益 | | | | |
| 其他综合收益 | 10,234.37 | 6,670.7 | 217.12 | 247.58 |
| 综合收益总额 | -61,891,400.48 | -33,800,577.96 | -438,946,907.43 | -107,028,179.95 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 774,902,035.8 | 858,223,312.73 | 844,488,891.49 | 821,861,726.47 |
| 非流动资产: | | | | |
| 非流动资产合计 | 1,402,816,734.29 | 1,436,198,198.89 | 1,468,015,790.14 | 1,758,462,913.7 |
| 资产总计 | 2,177,718,770.09 | 2,294,421,511.62 | 2,312,504,681.63 | 2,580,324,640.17 |
| 流动负债: | | | | |
| 流动负债合计 | 1,475,963,083.85 | 1,391,153,891.41 | 1,386,317,307.96 | 1,225,225,844.42 |
| 非流动负债: | | | | |
| 非流动负债合计 | 135,756,652.68 | 309,582,765.8 | 299,335,861.78 | 391,898,272.04 |
| 负债合计 | 1,611,719,736.53 | 1,700,736,657.21 | 1,685,653,169.74 | 1,617,124,116.46 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 597,671,330.75 | 623,576,331.82 | 653,771,461.34 | 965,430,860.79 |
| 股东权益合计 | 565,999,033.56 | 593,684,854.41 | 626,851,511.89 | 963,200,523.71 |
| 负债和股东权益合计 | 2,177,718,770.09 | 2,294,421,511.62 | 2,312,504,681.63 | 2,580,324,640.17 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 405,597,142.55 | 194,790,209.21 | 666,912,121.82 | 504,079,823.09 |
| 经营活动现金流出小计 | 361,869,087.17 | 162,016,783.23 | 606,484,143.73 | 456,436,916.02 |
| 经营活动产生的现金流量净额 | 43,728,055.38 | 32,773,425.98 | 60,427,978.09 | 47,642,907.07 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 1,000,000 | 1,000,000 | 60,435,289.4 | 55,437,259.4 |
| 投资活动现金流出小计 | 4,652,771.48 | 2,696,249.15 | 35,640,557.33 | 32,342,774.54 |
| 投资活动产生的现金流量净额 | -3,652,771.48 | -1,696,249.15 | 24,794,732.07 | 23,094,484.86 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 570,467,949.05 | 386,295,813.8 | 742,684,602.95 | 558,338,210.76 |
| 筹资活动现金流出小计 | 626,567,100.41 | 368,812,541.23 | 868,110,674.09 | 684,073,859.28 |
| 筹资活动产生的现金流量净额 | -56,099,151.36 | 17,483,272.57 | -125,426,071.14 | -125,735,648.52 |
| 汇率变动对现金及现金等价物的影响 | -2,243,235.62 | -812,194.26 | 784,310.61 | 827,636.97 |
| 现金及现金等价物净增加额 | -18,267,103.08 | 47,748,255.14 | -39,419,050.37 | -54,170,619.62 |
| 期末现金及现金等价物余额 | 249,491,111.73 | 315,506,469.95 | 267,758,214.81 | 253,006,645.56 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | -18,267,103.08 | - | -39,419,050.37 | - |